Seres Therapeutics (MCRB)
(Delayed Data from NSDQ)
$1.07 USD
+0.09 (9.41%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $1.06 -0.01 (-0.93%) 7:24 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MCRB 1.07 +0.09(9.41%)
Will MCRB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MCRB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MCRB
Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?
Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates
MCRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for MCRB
Biotech Alert: Searches spiking for these stocks today
Unusually active option classes on open June 25th
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer
12 Health Care Stocks Moving In Monday's Intraday Session
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)